Combined Effects of the Variants FSHB -211G>T and FSHR 2039A>G on Male Reproductive Parameters
Overview
Affiliations
Context: A polymorphism in the FSHB promoter (-211G>T, rs10835638) was shown to influence male serum FSH levels, whereas a polymorphism in the FSH receptor gene (FSHR; 2039A>G, rs6166) was previously shown to be associated with FSH levels in women only.
Objective: The objective of the study was to analyze the effects of both FSHB -211G>T and FSHR 2039A>G on male reproductive parameters.
Design And Setting: A total of 1213 German men attending an infertility clinic were genotyped by TaqMan assay.
Patients: Patients included male partners in infertile couples without known causes for male infertility.
Main Outcome Measures: An association analysis of single and combined single-nucleotide polymorphism genotypes with clinical parameters was performed.
Results: The FSHB -211G>T T-allele showed significant dosage effects for FSH (-0.51 U/liter per T-allele), LH (0.28 U/liter), and bitesticular volume (-3.2 ml). Statistical significance was enhanced severalfold after a meta-analysis comprising 3017 men. TT carriers were significantly more prevalent among men with lower sperm counts. The FSHR 2039A>G G-allele exhibited nonsignificant trends for associations with higher FSH and reduced testicular volumes. However, in the combined model, FSHR 2039A>G significantly modulated the more dominant effect of FSHB -211G>T on serum FSH and testicular volume among the T-allele carriers.
Conclusions: By analyzing both single-nucleotide polymorphisms for the first time, we convincingly show that indeed FSHR 2039A>G has an effect also in males. In the proposed model of the combined effects, FSHB -211G>T acts strongly on male reproductive parameters, whereas the FSHR 2039A>G effects were approximately 2-3 times smaller. Clinically this is of importance because oligozoospermic patients carrying unfavorable variants affecting FSH action may benefit from FSH treatment.
Santi D, Corona G, Salonia A, Ferlin A J Endocrinol Invest. 2025; .
PMID: 39804439 DOI: 10.1007/s40618-024-02524-x.
Cui Y, Zhou M, He Q, He Z Cells. 2023; 12(9).
PMID: 37174664 PMC: 10177581. DOI: 10.3390/cells12091264.
Cervan-Martin M, Tuttelmann F, Lopes A, Bossini-Castillo L, Rivera-Egea R, Garrido N Commun Biol. 2022; 5(1):1220.
PMID: 36357561 PMC: 9649734. DOI: 10.1038/s42003-022-04192-0.
Pallotti F, Barbonetti A, Rastrelli G, Santi D, Corona G, Lombardo F J Endocrinol Invest. 2022; 45(10):1807-1822.
PMID: 35349114 PMC: 8961097. DOI: 10.1007/s40618-022-01778-7.
Schubert M, Perez Lanuza L, Woste M, Dugas M, Carmona F, Palomino-Morales R J Clin Endocrinol Metab. 2022; 107(8):2350-2361.
PMID: 35305013 PMC: 9282256. DOI: 10.1210/clinem/dgac165.